Traded Jul 8 – Oct 15, 2026 · largest single transaction ~$9.8K
Show all 2 transactions
Oct 15, 2026~$9.8K · 108 sh @ $90.33
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
HQY · NASDAQ · Managed Health Care
HealthEquity (HQY) · oqro.io/stocks/HQY · printed today. Every figure comes from a public filing, linked on the page online. Not investment advice.
Yes. Insiders of HealthEquity (HQY) filed 2 open-market purchases in the last 90 days; the latest was filed on Oct 19, 2026.
Since 2014, HealthEquity insiders reported 15 open-market purchases and 535 sales on Forms 4 and 5, with purchases in 5 different years, most recently 2026.
In the last 90 days, 2 insiders of HealthEquity (HQY) reported 4 open-market sales worth $812K in total on SEC Form 4. The largest seller by value was Adrian T Dillon, with $798K. Many insider sales follow a plan set in advance or cover taxes on stock awards; the filing says what was sold, not the reason.
Yes. Members of Congress disclosed 3 trades in HealthEquity (HQY) in the last 12 months, each reported as a value range on a periodic transaction report. The most recent is from Rep. Gilbert Ray Cisneros Jr. (CA31).
HealthEquity's next results are expected on Dec 1, 2026. The date can move until the company confirms it. Insiders often trade in the weeks right after results.
From official filings only: SEC Forms 4, 5 and 144 for insiders, House and Senate periodic transaction reports for Congress, SEC Form 13F for funds, Form 8-K for company events and USAspending for federal contracts. Every record on OQRO links to its source. It is public data, not investment advice.
$94.75−2.63 (−2.70%)
Close of Nov 20, 2026, vs Nov 19 · end-of-day
−5.9% (−$5.98) from Nov 20, 2025 to Nov 20, 2026 · adjusted daily closes
Adjusted close went from $100.73 on Nov 20, 2025 to $94.75 on Nov 20, 2026 (−5.9%). Disclosed in this range: 6 insider trades, 9 pre-arranged insider sales, 3 Congress trades, and 18 13F position changes for 3 quarters ending in it.
Counts of filings OQRO holds, by the date each was filed or the award started. Every figure links to its official SEC, House, Senate or USAspending record.
Managed Health Care company based in Draper, Utah.
Last 12 months
−5.9%
Market value
$8.42B
S&P 500 +5.7% over the same dates. Prices adjusted for splits and dividends.
Short interest: 5.48M shares sold short (6.2% of shares outstanding), −7.9% vs the previous count, 7.5 days of normal trading to buy them back. FINRA, as of Oct 30, 2026. Short interest history
Revenue, fiscal 2026
$1.31B
+9.5% vs the year before
Net income, fiscal 2026
$215M
As reported in the annual filing
Shares outstanding
82.7M
As of Aug 20, 2026
In fiscal 2026 the company spent $299M buying back its own shares. Cash actually paid, from its cash-flow statement.
New federal contracts from the last 12 months add up to 1.93% of that revenue. Contract money is usually earned over several years, so this is a size comparison, not a share of sales.
Traded Jul 8 – Oct 15, 2026 · largest single transaction ~$9.8K
Oct 15, 2026~$9.8K · 108 sh @ $90.33
Jul 8, 2026~$2.2K · 23 sh @ $95.06
DetailsOfficial recordTraded Apr 22 – Aug 24, 2026 · largest single transaction ~$11KNot reported under a pre-arranged trading plan
Aug 24, 2026~$11K · 108 sh @ $105.60
DetailsOfficial recordApr 22, 2026~$1.9K · 23 sh @ $82.81
DetailsOfficial recordJames M. Lucania (Officer) plans to sell ~$257K of HealthEquity
Planned, from payPrices are daily closes from Polygon.io. Company figures come from its own SEC filings. Past moves are not a forecast. OQRO reports what was filed and never tells you what to buy or sell.
Insiders of HealthEquity reported 15 open-market purchases and 535 sales since 2014; purchases in 5 different years, most recently 2026.
| Year | Bought | Sold |
|---|---|---|
| 2026 | $12K2×2 trades | $2.46M9×9 trades |
| 2025 | — | $38.9M29×29 trades |
| 2024 | — | $25.5M38×38 trades |
| 2023 | — | $16.1M30×30 trades |
| 2022 | — | $3.83M8×8 trades |
| 2021 | $1.77M3×3 trades | $24.6M39×39 trades |
| 2020 | — | $11.9M18×18 trades |
| 2019 | $2.44M4×4 trades | $5.74M21×21 trades |
| 2018 | — | $75.8M75×75 trades |
| 2017 | $203K1×1 trade | $378M156×156 trades |
| 2016 | — | $257M69×69 trades |
| 2015 | — | $286M43×43 trades |
| 2014 | $1.06M5×5 trades | — |
Open-market purchases (code P) and sales (code S) on Forms 4 and 5. Up to Sep 2024 from the SEC's Insider Transactions Data Sets; since Oct 2024 from each filing as it is published. A trade filed twice (an amendment) counts once. Dollar totals use the price the filer reported; lines with no price count as trades without a value.
Written by software from the filings listed below · Nov 13, 2026
3 more points, with the facts they come from, are in OQRO Pro.
Sign up freeSource: SEC Schedules 13D and 13G, which anyone owning more than 5% of a class of stock must file. A 13D filer may seek to influence the company; a 13G filer is passive. Filings before December 2024 are free text and read from their cover page: a percent or share count that is not stated plainly is left blank. Each line links to the filing.
Written by OQRO's software from the last 12 months on record · Nov 19, 2026
Every number, name, date and link in the text above comes from this list; software checks that before the text is stored. This text was assembled directly from the facts, without a language model.
Insiders
Congress
Funds and stakes
Contracts, lobbying and filings
Company reports, price and press
Who holds it
Things to keep in mind
Records
Against the S&P 500 over the year
Since Nov 19, 2025, HQY is down 8.5% and the index fund is up 4.1%: 13 points behind the market. Traders call a stock that beats the index over a period a relative-strength leader.
How much HQY moves
Beta 0.4 (1 year vs SPY)
End-of-day prices. These figures describe the past year and say nothing about what comes next. Beta: how much the stock moved, on average, for each 1% move of the S&P 500 fund over 251 trading days (1 = in step with it).
1 certified in FY2026 Q3, vs 3 a year earlier. 1 position in total, median offered wage $143K a year.
Labor condition applications for H-1B workers certified by the Department of Labor, counted by decision date (FY2026 Q3: Apr 1, 2026 to Jun 30, 2026, the latest quarter published). A certified application is a step before a visa petition, not a hire or a visa, and one application can cover several positions. Matched by employer ID number or name.
Revenue
$351M
+7.6% vs the same quarter a year earlier
Free cash flow, last 12 months
$488M
This quarter $135M, a year earlier $135M
Net debt
$675M
Debt $931M, cash $256M, at Jul 31, 2026
Backlog
$3.1M
Work contracted but not yet delivered, as the company reports it
From the company's own quarterly and annual reports to the SEC. Free cash flow (cash from operations minus capital spending), net debt (debt minus cash) and 12-month totals are calculated by OQRO. Production rates, deliveries, approvals and guidance are in its results announcement of Aug 27, 2026.
Revenue and earnings history, 14 fiscal yearsEarnings dates and the stock's moves
Last results
Aug 27, 2026
More than 30 days ago
Next results, expected
Dec 1, 2026
Purchases after results
40%
4 of 10 insider purchases since 2016 came within 30 days after a results announcement
From HealthEquity's own results filings (8-K Item 2.02) and its insiders' Forms 4 and 5. Many companies only let insiders trade in a period after results; OQRO does not know HealthEquity's policy and only shows the pattern in the filings. A purchase made long after results, at a company whose insiders usually buy right after them, is marked “Bought outside the usual window”.
The three months May 1, 2026 to Jul 31, 2026, compared with the same quarter a year earlier, from the quarterly report filed Aug 27, 2026. Quarterly reports are not audited. Read the filing
+10% on the same quarter a year earlier ($160M)
+5.6% on the same quarter a year earlier ($118M)
+4.7% on the same quarter a year earlier ($48.1M)
Fiscal year Feb 1, 2025 to Jan 31, 2026, from the annual report filed Mar 17, 2026. Read the filing
+17% on the year before ($545M)
+1.4% on the year before ($478M)
+8.8% on the year before ($176M)
Every annual report has a section where the company's managers explain the year's results (Item 7, Management's discussion and analysis). In this report it runs to about 10,000 words.
We are a leader and an innovator in providing technology-enabled services that empower consumers to make healthcare saving, spending, and investing decisions. We use our innovative technology to manage consumers' tax-advantaged HSAs and other CDBs offered by employers, including FSAs and HRAs, and to administer COBRA, commuter and other benefits. As part of our services, we provide consumers with payment processing services, personalized benefit information, access to healthcare solutions through our marketplace, and investment advice to grow their tax-advantaged healthcare savings. The core of our offerings is the HSA, a financial account through which consumers save, spend, and invest their healthcare dollars on a tax-advantaged basis.
Source: SEC EDGAR, Form 10-K filed Mar 17, 2026 and Form 10-Q filed Aug 27, 2026. Revenue lines are the figures the company tags in its filing; OQRO shows a split only when its lines add up to the reported total revenue. The quote is the opening of the managers' discussion, cut at a sentence; the word count is estimated from its length. Not investment advice.
And 26 more headings in the filing.
Fails to deliver: 19K shares (about $1.93M) were not delivered on time for settlement on Oct 26, 2026. SEC fails-to-deliver data.
Fails to deliver have many causes, including processing delays, and are often resolved within days.
Off-exchange trading: 42.0% of the shares traded over the latest 4 published weeks changed hands away from the exchanges (31.3% on ATS, 10.7% with other brokers), close to its 26-week average of 41.4%. Weeks of Sep 21 to Oct 16, 2026.
Largest ATS: UBS ATS (14.0%), INTELLIGENT CROSS LLC (10.7%), SIGMA X2 (10.3%), as a share of this stock's ATS volume over the same 4 weeks.
An ATS, often called a dark pool, is a private trading venue run by a broker where orders are not shown publicly before they trade. Other off-exchange trades are mostly retail orders filled by wholesale brokers. A high share is common and says nothing by itself about where the price goes. FINRA OTC Transparency data, published 2 weeks after each week for the largest stocks and 4 weeks for others; total volume from our daily price data.
Latest annual report filed Mar 17, 2026, compared with the one filed Mar 18, 2025. Read the filing
For information regarding legal proceedings in which we are involved, refer to Note 6—Commitments and contingencies to our financial statements included in Part II, Item 8 of this Annual Report on Form 10-K.
The company describes its cases in the notes to its financial statements, in the same filing.
Source: SEC EDGAR, Form 10-K filed Mar 17, 2026. Headings are the titles the company gives each risk; OQRO compares them with the year before by their words, so a heading that was reworded a lot shows up as both new and no longer listed. Companies list the risks they face, not forecasts.